<?xml version="1.0" encoding="UTF-8"?>
<rss xmlns:atom="http://www.w3.org/2005/Atom" xmlns:dc="http://purl.org/dc/elements/1.1/" version="2.0">
  <channel>
    <title>AlloTera Therapeutics</title>
    <link>https://www.biospace.com/employer/2394503/wugen</link>
    <description>AlloTera Therapeutics</description>
    <language>en-US</language>
    <lastBuildDate>Wed, 16 Mar 2022 13:25:43 GMT</lastBuildDate>
    <atom:link href="https://www.biospace.com/employer/2394503/wugen.rss" type="application/rss+xml" rel="self" />
    <item>
      <title>Four Cancer Clinical Trials Advance with Blessing of FDA</title>
      <link>https://www.biospace.com/cancer-clinical-trials-moving-forward-with-fda-approval</link>
      <dc:creator>Hayley Shasteen</dc:creator>
      <description>Several biopharma companies celebrate the U.S. Food and Drug Administration’s approval for clinical trials involving therapeutics for cancer treatment.</description>
      <pubDate>Wed, 16 Mar 2022 13:25:43 GMT</pubDate>
      <guid>https://www.biospace.com/cancer-clinical-trials-moving-forward-with-fda-approval</guid>
    </item>
    <item>
      <title>Clinical Catch-Up: New SMA and Alzheimer's Data</title>
      <link>https://www.biospace.com/clinical-catch-up-march-14-18</link>
      <dc:creator>Mark Terry</dc:creator>
      <description>It was a busy week for clinical trial announcements. Here's a look.</description>
      <pubDate>Fri, 18 Mar 2022 14:22:44 GMT</pubDate>
      <guid>https://www.biospace.com/clinical-catch-up-march-14-18</guid>
    </item>
    <item>
      <title>Scrambling for Talent and More Office Space, Life Sciences Companies Relocate</title>
      <link>https://www.biospace.com/scrambling-for-talent-and-more-office-space-biotech-companies-keep-relocating</link>
      <dc:creator>Hannah Chudleigh</dc:creator>
      <description>Dozens of life sciences companies are relocating to accommodate more employees and production capacities.</description>
      <pubDate>Fri, 01 Apr 2022 15:06:56 GMT</pubDate>
      <guid>https://www.biospace.com/scrambling-for-talent-and-more-office-space-biotech-companies-keep-relocating</guid>
    </item>
    <item>
      <title>Wugen Announces Data Presentation at the 63rd Annual Society of Hematology (ASH) Annual Meeting</title>
      <link>https://www.biospace.com/wugen-announces-data-presentation-at-the-63rd-annual-society-of-hematology-ash-annual-meeting</link>
      <description>Wugen Announces Data Presentation at the 63rd Annual Society of Hematology (ASH) Annual Meeting</description>
      <pubDate>Thu, 04 Nov 2021 19:26:07 GMT</pubDate>
      <guid>https://www.biospace.com/wugen-announces-data-presentation-at-the-63rd-annual-society-of-hematology-ash-annual-meeting</guid>
    </item>
    <item>
      <title>Wugen Announces Data Presentation at The Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting</title>
      <link>https://www.biospace.com/wugen-announces-data-presentation-at-the-society-for-immunotherapy-of-cancer-s-sitc-36th-annual-meeting</link>
      <description>Wugen Announces Data Presentation at The Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting</description>
      <pubDate>Tue, 09 Nov 2021 13:06:38 GMT</pubDate>
      <guid>https://www.biospace.com/wugen-announces-data-presentation-at-the-society-for-immunotherapy-of-cancer-s-sitc-36th-annual-meeting</guid>
    </item>
    <item>
      <title>Wugen to Present Virtually at the Upcoming Jefferies London Healthcare Conference</title>
      <link>https://www.biospace.com/wugen-to-present-virtually-at-the-upcoming-jefferies-london-healthcare-conference</link>
      <description>Wugen, Inc. today announced that management will participate in the upcoming Virtual Jefferies London Healthcare Conference set to take place November 16 - 19, 2021.</description>
      <pubDate>Wed, 10 Nov 2021 13:06:20 GMT</pubDate>
      <guid>https://www.biospace.com/wugen-to-present-virtually-at-the-upcoming-jefferies-london-healthcare-conference</guid>
    </item>
    <item>
      <title>Wugen Presents New Preclinical Data from Novel Memory Natural Killer (NK) Platform at The Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting</title>
      <link>https://www.biospace.com/wugen-presents-new-preclinical-data-from-novel-memory-natural-killer-nk-platform-at-the-society-for-immunotherapy-of-cancer-s-sitc-36th-annual-meeting</link>
      <description>Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of off-the-shelf cell therapies to treat a broad range of hematological and solid tumor malignancies, today presented new data from its best-in-class memory natural killer (NK) cell therapy platform at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting.</description>
      <pubDate>Fri, 12 Nov 2021 12:06:57 GMT</pubDate>
      <guid>https://www.biospace.com/wugen-presents-new-preclinical-data-from-novel-memory-natural-killer-nk-platform-at-the-society-for-immunotherapy-of-cancer-s-sitc-36th-annual-meeting</guid>
    </item>
    <item>
      <title>Wugen Presents New Preclinical Data Supporting the Safety and Efficacy of WU-CART-007 for T-Cell Malignancies at the 63rd Annual Society of Hematology (ASH) Annual Meeting</title>
      <link>https://www.biospace.com/wugen-presents-new-preclinical-data-supporting-the-safety-and-efficacy-of-wu-cart-007-for-t-cell-malignancies-at-the-63rd-annual-society-of-hematology-ash-annual-meeting</link>
      <description>Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of off-the-shelf cell therapies to treat a broad range of hematological and solid tumor malignancies, presented new preclinical data supporting the safety and efficacy profile of WU-CART-007 for T-cell malignancies.</description>
      <pubDate>Sun, 12 Dec 2021 14:06:06 GMT</pubDate>
      <guid>https://www.biospace.com/wugen-presents-new-preclinical-data-supporting-the-safety-and-efficacy-of-wu-cart-007-for-t-cell-malignancies-at-the-63rd-annual-society-of-hematology-ash-annual-meeting</guid>
    </item>
    <item>
      <title>Wugen to Present Virtually at the Upcoming Oppenheimer 32nd Annual Healthcare Conference</title>
      <link>https://www.biospace.com/wugen-to-present-virtually-at-the-upcoming-oppenheimer-32nd-annual-healthcare-conference</link>
      <description>Wugen, Inc. today announced that management will present virtually at the Oppenheimer 32nd Annual Healthcare Conference on Wednesday, March 16, 2022 at 4:00 p.m. ET.</description>
      <pubDate>Wed, 09 Mar 2022 13:06:19 GMT</pubDate>
      <guid>https://www.biospace.com/wugen-to-present-virtually-at-the-upcoming-oppenheimer-32nd-annual-healthcare-conference</guid>
    </item>
    <item>
      <title>Wugen Announces First Patient Dosed in Phase 1/2 Trial of WU-CART-007 for the Treatment of Patients with R/R T-ALL/LBL</title>
      <link>https://www.biospace.com/wugen-announces-first-patient-dosed-in-phase-1-2-trial-of-wu-cart-007-for-the-treatment-of-patients-with-r-r-t-all-lbl</link>
      <description>Wugen, Inc. today announced that the first patient has been dosed in a Phase 1/2 trial of WU-CART-007 for the treatment of relapsed or refractory (R/R) T-cell acute lymphoblastic leukemia (T-ALL)/lymphoblastic lymphoma (LBL).</description>
      <pubDate>Tue, 15 Mar 2022 11:06:25 GMT</pubDate>
      <guid>https://www.biospace.com/wugen-announces-first-patient-dosed-in-phase-1-2-trial-of-wu-cart-007-for-the-treatment-of-patients-with-r-r-t-all-lbl</guid>
    </item>
  </channel>
</rss>
